Transactions involving the acquisition of FDA-regulated firms and/or the licensing of products present unique challenges during the due diligence process. This session focuses on best practices and real-life examples of pitfalls that make or break the deal as they relate to intellectual property issues, clinical research, and regulatory requirements including:
- Projecting the scope of exclusionary rights on the product
- How the “useful” life cycle of a patent impacts transaction value and associated risks
- Evaluating the risks associated with patent litigation with respect to small molecules and follow-on biologics
- Understanding the clinical research and development program – how to maximize potential for success
- What can go wrong with clinical trials and practical suggestions to ensure compliance
- Identifying critical aspects of FDA regulatory authority relative to a diligence review
- Determining regulatory pathways towards product approval
- Prospecting opportunities to increase product life cycles
Panelists include: Doug Carsten, Partner, Foley; Jeff Miller, VP, Regulatory Affairs and Quality Assurance, Icon Clinical Research; David Rosen, Co-Chair, Life Sciences Team, Foley.
Related Insights
August 11, 2025
Labor & Employment Law Perspectives
Washington State Expands Paid Sick Leave Law To Include Coverage for Immigration Proceedings and Hate Crime Victims
As we have previously discussed, state paid sick leave laws continue expanding. In 2025, states which previously had no sick leave…
August 11, 2025
Labor & Employment Law Perspectives
2025 Changes in Texas Employment Laws That Employers Must Comply With
As we pass the halfway point of 2025, there has already been a flurry of legislative changes and court decisions that have changed the…
August 8, 2025
Foley Ignite
The Rise of "Acquihiring" in a Post-Layoff Tech Sector
As a practicing M&A attorney representing both strategic acquirers and venture-backed targets, I have had a front row seat to the…